|
Malignant neoplasm of breast
|
|
0.050 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Breast Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Malignant neoplasm of breast
|
|
0.050 |
GeneticVariation
|
BEFREE |
The aim of the present study was to evaluate the association between the FGFR4 Gly388Arg polymorphism and breast cancer risk as well as clinicopathological parameters of the patients.
|
20066896 |
2009 |
|
Breast Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
The aim of the present study was to evaluate the association between the FGFR4 Gly388Arg polymorphism and breast cancer risk as well as clinicopathological parameters of the patients.
|
20066896 |
2009 |
|
Breast Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
G388R mutation of the FGFR4 gene is not relevant for breast cancer prognosis.
|
14710228 |
2004 |
|
Malignant neoplasm of breast
|
|
0.050 |
GeneticVariation
|
BEFREE |
G388R mutation of the FGFR4 gene is not relevant for breast cancer prognosis.
|
14710228 |
2004 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Our results suggest that the FGFR4 Gly388Arg polymorphism is not a risk factor for GC cancer initiation but that it is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or at an early clinical stage.
|
23901234 |
2013 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
For the rs351855 (Arg388) locus, we observed a reduced HCC risk associated with the T variant genotypes, particularly for those whose tumors with gross portal vein tumor thrombosis (gross PVTT) (OR = 0.66; 95% confidence interval, 95% CI = 0.46-0.95 for CT + TT).
|
21656577 |
2012 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
In OSCC, the FGFR4 Gly388Arg polymorphism and the presence or absence of mutation in TP53 did not show a significant association with the clinicopathological features of the tumors at surgery.
|
20127014 |
2010 |
|
Malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
Stratified analysis by cancer type indicated the rs351855 G>A polymorphism was associated with an increased risk of breast and prostate cancer, but a decreased risk of lung cancer.
|
28445975 |
2017 |
|
Carcinoma of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
Stratified analysis by cancer type indicated the rs351855 G>A polymorphism was associated with an increased risk of breast and prostate cancer, but a decreased risk of lung cancer.
|
28445975 |
2017 |
|
Primary malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
Stratified analysis by cancer type indicated the rs351855 G>A polymorphism was associated with an increased risk of breast and prostate cancer, but a decreased risk of lung cancer.
|
28445975 |
2017 |
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
Thus, our findings elucidate the molecular mechanism behind the genetic association of rs351855 with accelerated cancer progression and suggest that germline variants of cell-surface molecules that recruit STAT3 to the inner cell membrane are a significant risk for cancer prognosis and disease progression.
|
26675719 |
2015 |
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
This LOH involved the FGFR4-WT allele as frequently as the cancer progression-associated FGFR4-G388R polymorphic allele.
|
21037081 |
2010 |
|
Malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
|
19296538 |
2009 |
|
Carcinoma of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
|
19296538 |
2009 |
|
Primary malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
|
19296538 |
2009 |
|
Carcinoma of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
While we employed a comprehensive set of statistical tests, including those sensitive to the detection of differences in early survival, our data provide little evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis.
|
17519899 |
2007 |
|
Primary malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
While we employed a comprehensive set of statistical tests, including those sensitive to the detection of differences in early survival, our data provide little evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis.
|
17519899 |
2007 |
|
Malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
While we employed a comprehensive set of statistical tests, including those sensitive to the detection of differences in early survival, our data provide little evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis.
|
17519899 |
2007 |
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
Three other nonparametric linear rank-tests particularly suitable for investigating possible relations between G388R mutation and early cancer progression were also used.
|
14710228 |
2004 |
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
There was no statistic difference in FGFR4 rs351855 genotype distribution between the patients group and control group (P > 0.05), among which the risk of chemotherapy failure on GA + AA patients was 3.257 times as much as that of the GG patients, and the risk of recurrence or metastasis of GA + AA patients was 2.783 times as much as that of the GG patients.
|
28870344 |
2017 |
|
Squamous cell carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility.
|
29221201 |
2017 |
|
Node-positive breast cancer
|
|
0.020 |
GeneticVariation
|
BEFREE |
Analyses of the disease characteristics showed that SNP rs351855 was associated with lymph-node-positive breast cancer with a dose-dependent effect of the minor allele (P = 0.008).
|
26431494 |
2015 |